KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Xenon Pharmaceuticals (XENE) EPS (Weighted Average and Diluted) (2016 - 2025)

Xenon Pharmaceuticals (XENE) has disclosed EPS (Weighted Average and Diluted) for 13 consecutive years, with -$1.31 as the latest value for Q4 2025.

  • On a quarterly basis, EPS (Weighted Average and Diluted) fell 57.83% to -$1.31 in Q4 2025 year-over-year; TTM through Dec 2025 was -$4.36, a 44.85% decrease, with the full-year FY2025 number at -$4.36, down 44.85% from a year prior.
  • EPS (Weighted Average and Diluted) was -$1.31 for Q4 2025 at Xenon Pharmaceuticals, down from -$1.15 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of -$0.35 in Q1 2022 to a low of -$1.31 in Q4 2025.
  • A 5-year average of -$0.71 and a median of -$0.65 in 2023 define the central range for EPS (Weighted Average and Diluted).
  • Peak YoY movement for EPS (Weighted Average and Diluted): crashed 80.0% in 2023, then grew 1.59% in 2024.
  • Xenon Pharmaceuticals' EPS (Weighted Average and Diluted) stood at -$0.48 in 2021, then decreased by 18.75% to -$0.57 in 2022, then fell by 14.04% to -$0.65 in 2023, then decreased by 27.69% to -$0.83 in 2024, then crashed by 57.83% to -$1.31 in 2025.
  • Per Business Quant, the three most recent readings for XENE's EPS (Weighted Average and Diluted) are -$1.31 (Q4 2025), -$1.15 (Q3 2025), and -$1.07 (Q2 2025).